Celltrion to invest $805 mil. for Incheon facility expansion

Celltrion will invest 1.2 trillion won ($805 million) to expand its drug substance production facility at its headquarters in Incheon, while setting the expansion capacity at its U.S. production site at 75,000 liters per year, bringing the company’s total annual production capacity to 570,000 liters. Celltrion said Tuesday the investment will be carried out in multiple phases from this year through 2030, describing it as a mid- to long-term growth initiative aimed at ensuring stable production and supply of next-generation biosimilars and drugs under development. At its Songdo campus in Incheon, Celltrion will invest 1.2 trillion won to establish Plants 4 and 5, which will have a combined annual production capacity of 180,000 liters of drug substances. Plants 4 and 5 will be equipped with automation systems and smart factory technologies to maximize production efficiency and flexibility, enabling both small-batch, multi-product manufacturing and large-scale mass production. This will allow the company to respond more quickly to production needs for its current key products as well as

Go to News Site